Female reproductive aging and menopause

Physiological Basis of Aging and Geriatrics, Fourth Edition

Volumn , Issue , 2007, Pages 159-184

  Bellino, Francis ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956253714     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (200)

1. Cohen AA. Female post-reproductive lifespan: a general mammalian trait. Biol Rev Camb Philos Soc 2004; 79(4): 733-750.
2. Wise PM, Smith MJ, Dubal DB, et al. Neuroendocrine modulation and repercussions of female reproductive aging. Recent Prog Horm Res 2002; 57: 235-256.
3. Brann DW, Mahesh VB. The aging reproductive neuroendocrine axis. Steroids 2005; 70(4): 273-283.
4. Bellino FL. Nonprimate animal models of menopause: workshop report. Menopause 2000; 7(1): 14-24.
5. Bellino FL, Wise PM. Nonhuman primate models of menopause workshop. Biol Reprod 2003; 68(1): 10-18.
6. Nichols SM, Bavister BD, Brenner CA, et al. Ovarian senescence in the rhesus monkey (Macaca mulatta). Hum Reprod 2005; 20(1): 79-83.
7. Kavanagh K, Koudy WJ, Wagner JD. Naturally occurring menopause in cynomolgus monkeys: changes in hormone, lipid, and carbohydrate measures with hormonal status. J Med Primatol 2005; 34(4): 171-177.
8. Martin LJ, Carey KD, Comuzzie AG. Variation in menstrual cycle length and cessation of menstruation in captive raised baboons. Mech Ageing Dev 2003; 124(8-9): 865-871.
9. Danilovich N, Ram SM. Recent female mouse models displaying advanced reproductive aging. Exp Gerontol 2006; 41(2): 117-122.
10. Appt SE, Kaplan JR, Clarkson TB, et al. Destruction of primordial ovarian follicles in adult cynomolgus macaques after exposure to 4-vinylcyclohexene diepoxide: a nonhuman primate model of the menopausal transition. Fertil Steril 2006; 86(suppl 4): 1210-1216.
11. Gosden RG, Laing SC, Felicio LS, et al. Imminent oocyte exhaustion and reduced follicular recruitment mark the transition to acyclicity in aging C57BL/6J mice. Biol Reprod 1983; 28(2): 255-260.
12. Nelson JF, Felicio LS, Randall PK, et al. A longitudinal study of estrous cyclicity in aging C57BL/6J mice: I. Cycle frequency, length and vaginal cytology. Biol Reprod 1982; 27(2): 327-339.
13. Inbred and genetically defined strains of laboratory animals; Part 1 Mouse and Rat. Bethesda, MD: Federation of American Societies for Experimental Biology, 1979.
14. Wu JM, Zelinski MB, Ingram DK, et al. Ovarian aging and menopause: current theories, hypotheses, and research models. Exp Biol Med (Maywood) 2005; 230(11): 818-828.
15. Perls TT, Fretts RC. The evolution of menopause and human life span. Ann Hum Biol 2001; 28(3): 237-245.
16. Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001; 153(9): 865-874.
17. Santoro N, Crawford SL, Allsworth JE, et al. Assessing menstrual cycles with urinary hormone assays. Am J Physiol Endocrinol Metab 2003; 284(3): E521-E530.
18. Kaufert P, Lock M, McKinlay S, et al. Menopause research: the Korpilampi workshop. Soc Sci Med 1986; 22(11): 1285-1289.
19. Soules MR, Sherman S, Parrott E, et al. Executive summary: stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001; 76(5): 874-878.
20. Mansfield PK, Carey M, Anderson A, et al. Staging the menopausal transition: data from the TREMIN Research Program on Women’s Health. Women’s Health Issues 2004; 14(6): 220-226.
21. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992; 14(2): 103-115.
22. Mitchell ES, Woods NF, Mariella A. Three stages of the menopausal transition from the Seattle Midlife Women’s Health Study: toward a more precise definition. Menopause 2000; 7(5): 334-349.
23. Dudley EC, Hopper JL, Taffe J, et al. Using longitudinal data to define the perimenopause by menstrual cycle characteristics. Climacteric 1998; 1(1): 18-25.
24. Treloar AE, Boynton RE, Behn BG, et al. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967; 12(1 Pt 2): 77-126.
25. Lisabeth LD, Harlow SD, Gillespie B, et al. Staging reproductive aging: a comparison of proposed bleeding criteria for the menopausal transition. Menopause 2004; 11(2): 186-197.
26. Miro F, Parker SW, Aspinall LJ, et al. Sequential classification of endocrine stages during reproductive aging in women: the FREEDOM study. Menopause 2005; 12(3): 281-290.
27. http://www.pop.psu.edu/tremin/tremin.htm (accessed Nov 2006).
28. Avis NE, McKinlay SM. The Massachusetts Women’s Health Study: an epidemiologic investigation of the menopause. J Am Med Women Assoc 1995; 50(2): 45-9: 63.
29. Johannes CB, Crawford SL, McKinlay JB. Interviewer effects in a cohort study. Results from the Massachusetts Women’s Health Study. Am J Epidemiol 1997; 146(5): 429-438.
30. Woods NF, Mariella A, Mitchell ES. Depressed mood symptoms during the menopausal transition: observations from the Seattle Midlife Women’s Health Study. Climacteric 2006; 9(3): 195-203.
31. Mitchell ES, Woods NF. Symptom experiences of midlife women: observations from the Seattle Midlife Women’s Health Study. Maturitas 1996; 25(1): 1-10.
32. http://www.psychiatry.unimelb.edu.au/midlife (accessed Nov 2006).
33. Taffe JR, Dennerstein L. Menstrual patterns leading to the final menstrual period. Menopause 2002; 9(1): 32-40.
34. Burger HG, Dudley EC, Hopper JL, et al. The endocrinology of the menopausal transition: a cross-sectional study of a population- based sample. J Clin Endocrinol Metab 1995; 80(12): 3537-3545.
35. http://www.edc.gsph.pitt.edu/swan/public/(accessed Nov 2006).
36. Sowers M, Crawford S, Sternfeld B, et al. SWAN: a multicenter, multiethnic, community-based cohort study of women and the menopausal transition. In: Lobo R, Kelsey J, Marcus R, eds. Menopause: Biology and Pathobiology. New York: Academic Press, 2000: 175-188.
37. http://www.swanrepository.com (accessed Nov 2006).
38. Gracia CR, Sammel MD, Freeman EW, et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause 2005; 12(2): 128-135.
39. Nelson DB, Sammel MD, Freeman EW, et al. Predicting participation in prospective studies of ovarian aging. Menopause 2004; 11(5): 543-548.
40. http://depts.washington.edu/endolab/BIMORA.shtml (accessed Nov 2006).
41. Ferrell RJ, O’Connor KA, Rodriguez G, et al. Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in steroid hormones and menstrual cycle lengths with age. Menopause 2005; 12(5): 567-577.
42. Lee SJ, Lenton EA, Sexton L, et al. The effect of age on the cyclical patterns of plasma LH, FSH, oestradiol and progesterone in women with regular menstrual cycles. Hum Reprod 1988; 3(7): 851-855.
43. Klein NA, Houmard BS, Hansen KR, et al. Age-related analysis of inhibin A, inhibin B, and activin a relative to the intercycle monotropic follicle-stimulating hormone rise in normal ovulatory women. J Clin Endocrinol Metab 2004; 89(6): 2977-2981.
44. Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999; 84(11): 4025-4030.
45. Henrich JB, Hughes JP, Kaufman SC, et al. Limitations of folliclestimulating hormone in assessing menopause status: findings from the National Health and Nutrition Examination Survey (NHANES 1999-2000)*. Menopause 2006; 13(2): 171-177.
46. Klein NA, Battaglia DE, Fujimoto VY, et al. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab 1996; 81(3): 1038-1045.
47. Klein NA, Illingworth PJ, Groome NP, et al. Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab 1996; 81(7): 2742-2745.
48. Miro F, Aspinall LJ. The onset of the initial rise in folliclestimulating hormone during the human menstrual cycle. Hum Reprod 2005; 20(1): 96-100.
49. Santoro N, Brown JR, Adel T, et al. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996; 81(4): 1495-1501.
50. van ZP, Scheffer GJ, Broekmans FJ, et al. Do cycle disturbances explain the age-related decline of female fertility? Cycle characteristics of women aged over 40 years compared with a reference population of young women. Hum Reprod 2003; 18(3): 495-501.
51. Miro F, Parker SW, Aspinall LJ, et al. Relationship between follicle-stimulating hormone levels at the beginning of the human menstrual cycle, length of the follicular phase and excreted estrogens: the FREEDOM study. J Clin Endocrinol Metab 2004; 89(7): 3270-3275.
52. Bernard DJ, Chapman SC, Woodruff TK. Mechanisms of inhibin signal transduction. Recent Prog Horm Res 2001; 56: 417-450.
53. Groome NP, Illingworth PJ, O’Brien M, et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996; 81(4): 1401-1405.
54. Muttukrishna S, Child T, Lockwood GM, et al. Serum concentrations of dimeric inhibins, activin A, gonadotrophins and ovarian steroids during the menstrual cycle in older women. Hum Reprod 2000; 15(3): 549-556.
55. Welt CK, McNicholl DJ, Taylor AE, et al. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 1999; 84(1): 105-111.
56. Burger HG, Dudley E, Mamers P, et al. Early follicular phase serum FSH as a function of age: the roles of inhibin B, inhibin A and estradiol. Climacteric 2000; 3(1): 17-24.
57. Reame NE, Kelche RP, Beitins IZ, et al. Age effects of folliclestimulating hormone and pulsatile luteinizing hormone secretion across the menstrual cycle of premenopausal women. J Clin Endocrinol Metab 1996; 81(4): 1512-1518.
58. Rannevik G, Jeppsson S, Johnell O, et al. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995; 21(2): 103-113.
59. Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 1998; 19(4): 397-428.
60. Burger HG, Cahir N, Robertson DM, et al. Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. Clin Endocrinol (Oxf) 1998; 48(6): 809-813.
61. Hansen KR, Thyer AC, Sluss PM, et al. Reproductive ageing and ovarian function: is the early follicular phase FSH rise necessary to maintain adequate secretory function in older ovulatory women? Hum Reprod 2005; 20(1): 89-95.
62. Welt CK, Jimenez Y, Sluss PM, et al. Control of estradiol secretion in reproductive ageing. Hum Reprod 2006; 21(8): 2189-2193.
63. Piltonen T, Koivunen R, Ruokonen A, et al. Ovarian age-related responsiveness to human chorionic gonadotropin. J Clin Endocrinol Metab 2003; 88(7): 3327-3332.
64. Landgren BM, Collins A, Csemiczky G, et al. Menopause transition: annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause. J Clin Endocrinol Metab 2004; 89(6): 2763-2769.
65. Miro F, Parker SW, Aspinall LJ, et al. Origins and consequences of the elongation of the human menstrual cycle during the menopausal transition: the FREEDOM Study. J Clin Endocrinol Metab 2004; 89(10): 4910-4915.
66. Santoro N, Lasley B, McConnell D, et al. Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: the Study ofWomen’s Health across the Nation (SWAN) Daily Hormone Study. J Clin Endocrinol Metab 2004; 89(6): 2622-2631.
67. Longcope C, Franz C, Morello C, et al. Steroid and gonadotropin levels in women during the peri-menopausal years. Maturitas 1986; 8(3): 189-196.
68. Randolph JF Jr, Sowers M, Bondarenko IV, et al. Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab 2004; 89(4): 1555-1561.
69. Zuckerman S. The number of oocytes in the mature ovary. Recent Prog Horm Res 1951; 6: 63-108.
70. Block E. Quantitative morphological investigations of the follicular system in women; variations at different ages. Acta Anat (Basel) 1952; 14(1-2): 108-123.
71. Peters H, Byskov AG, Himelstein-Braw R, et al. Follicular growth: the basic event in the mouse and human ovary. J Reprod Fertil 1975; 45(3): 559-566.
72. Tilly JL. Commuting the death sentence: how oocytes strive to survive. Nat Rev Mol Cell Biol 2001; 2(11): 838-848.
73. Fortune JE. Ovarian follicular growth and development in mammals. Biol Reprod 1994; 50(2): 225-232.
74. Hillier SG. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod 1994; 9(2): 188-191.
75. Gougeon A. Ovarian follicular growth in humans: ovarian ageing and population of growing follicles. Maturitas 1998; 30(2): 137-142.
76. Hirshfield AN. Overview of ovarian follicular development: considerations for the toxicologist. Environ Mol Mutagen 1997; 29(1): 10-15.
77. Johnson J, Bagley J, Skaznik-Wikiel M, et al. Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood. Cell 2005; 122(2): 303-315.
78. Kerr JB, Duckett R, Myers M, et al. Quantification of healthy follicles in the neonatal and adult mouse ovary: evidence for maintenance of primordial follicle supply. Reproduction 2006; 132(1): 95-109.
79. Bukovsky A, Caudle MR, Svetlikova M, et al. Oogenesis in adult mammals, including humans: a review. Endocrine 2005; 26(3): 301-316.
80. Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 1987; 65(6): 1231-1237.
81. Faddy MJ, Gosden RG, Gougeon A, et al. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod 1992; 7(10): 1342-1346.
82. Pavlik EJ, DePriest PD, Gallion HH, et al. Ovarian volume related to age. Gynecol Oncol 2000; 77(3): 410-412.
83. Bastos CA, Oppermann K, Fuchs SC, et al. Determinants of ovarian volume in pre-, menopausal transition, and post-menopausal women: a population-based study. Maturitas 2006; 53(4): 405-412.
84. Andolf E, Jorgensen C, Svalenius E, et al. Ultrasound measurement of the ovarian volume. Acta Obstet Gynecol Scand 1987; 66(5): 387-389.
85. Goswamy RK, Campbell S, Royston JP, et al. Ovarian size in postmenopausalwomen. Br J Obstet Gynaecol 1988; 95(8): 795-801.
86. Pavlik EJ, Liu C, DePriest PD, et al. Relating ovarian size to age, menopausal status, and use of hormones. Gynecol Oncol 2001; 80(2): 333-334.
87. Thatcher SS, Naftolin F. The aging and aged ovary. Seminars in Reproductive Endocrinology 1991; 9(3): 189-199.
88. Rinaudo P, Strauss JF, III. Endocrine function of the postmenopausal ovary. Endocrinol Metab Clin North Am 2004; 33(4): 661-674.
89. Costoff A, Mahesh VB. Primordial follicles with normal oocytes in the ovaries of postmenopausal women. J Am Geriatr Soc 1975; 23(5): 193-196.
90. Longcope C, Hunter R, Franz C. Steroid secretion by the postmenopausal ovary.AmJ Obstet Gynecol 1980; 138(5): 564-568.
91. Dennefors BL, Janson PO, Hamberger L, et al. Hilus cells from human postmenopausal ovaries: gonadotrophin sensitivity, steroid and cyclic AMP production. Acta Obstet Gynecol Scand 1982; 61(5): 413-416.
92. Dennefors BL, Janson PO, Knutson F, et al. Steroid production and responsiveness to gonadotropin in isolated stromal tissue of human postmenopausal ovaries. Am J Obstet Gynecol 1980; 136(8): 997-1002.
93. Peluso JJ, Steger RW, Jaszczak S, et al. Gonadotropin binding sites in human postmenopausal ovaries. Fertil Steril 1976; 27(7): 789-795.
94. Inkster SE, Brodie AM. Expression of aromatase cytochrome P-450 in premenopausal and postmenopausal human ovaries: an immunocytochemical study. J Clin Endocrinol Metab 1991; 73(4): 717-726.
95. Adashi EY. The climacteric ovary as a functional gonadotropin- driven androgen-producing gland. Fertil Steril 1994; 62(1): 20-27.
96. Plouffe L Jr. Ovaries, androgens and the menopause: practical applications. Semin Reprod Endocrinol 1998; 16(2): 117-120.
97. Couzinet B, Meduri G, Lecce MG, et al. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 2001; 86(10): 5060-5066.
98. Jabara S, Christenson LK, Wang CY, et al. Stromal cells of the human postmenopausal ovary display a distinctive biochemical and molecular phenotype. J Clin Endocrinol Metab 2003; 88(1): 484-492.
99. Nagamani M, Urban RJ. Expression of messenger ribonucleic acid encoding steroidogenic enzymes in postmenopausal ovaries. J Soc Gynecol Investig 2003; 10(1): 37-40.
100. Havelock JC, Rainey WE, Bradshaw KD, et al. The postmenopausal ovary displays a unique pattern of steroidogenic enzyme expression. Hum Reprod 2006; 21(1): 309-317.
101. Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90(7): 3847-3853.
102. Wildt L, Hausler A, Marshall G, et al. Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey. Endocrinology 1981; 109(2): 376-385.
103. Nippoldt TB, Reame NE, Kelch RP, et al. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle. J Clin Endocrinol Metab 1989; 69(1): 67-76.
104. Urban RJ, Johnson ML, Veldhuis JD. In vivo biological validation and biophysical modeling of the sensitivity and positive accuracy of endocrine peak detection. II. The follicle-stimulating hormone pulse signal. Endocrinology 1991; 128(4): 2008-2014.
105. Pincus SM, Veldhuis JD, Mulligan T, et al. Effects of age on the irregularity of LH and FSH serum concentrations in women and men. Am J Physiol 1997; 273(5 Pt 1): E989-E995.
106. Wilshire GB, Loughlin JS, Brown JR, et al. Diminished function of the somatotropic axis in older reproductive-aged women. J Clin Endocrinol Metab 1995; 80(2): 608-613.
107. Klein NA, Battaglia DE, Clifton DK, et al. The gonadotropin secretion pattern in normal women of advanced reproductive age in relation to the monotropic FSH rise. J Soc Gynecol Investig 1996; 3(1): 27-32.
108. Matt DW, Kauma SW, Pincus SM, et al. Characteristics of luteinizing hormone secretion in younger versus older premenopausal women. Am J Obstet Gynecol 1998; 178(3): 504-510.
109. Gore AC, Windsor-Engnell BM, Terasawa E. Menopausal increases in pulsatile gonadotropin-releasing hormone release in a nonhuman primate (Macaca mulatta). Endocrinology 2004; 145(10): 4653-4659.
110. Weiss G, Skurnick JH, Goldsmith LT, et al. Menopause and hypothalamic-pituitary sensitivity to estrogen. JAMA 2004; 292(24): 2991-2996.
111. Wise PM, Kashon ML, Krajnak KM, et al. Aging of the female reproductive system: a window into brain aging. Recent Prog Horm Res 1997; 52: 279-303.
112. Yin W, Gore AC. Neuroendocrine control of reproductive aging: roles of GnRH neurons. Reproduction 2006; 131(3): 403-414.
113. Celermajer DS, Sorensen KE, Spiegelhalter DJ, et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994; 24(2): 471-476.
114. Bandinelli S, Lauretani F, Benvenuti E, et al. Understanding the physiological and functional consequences of menopause: the PROSALMEN study. PROgetto SALute MENopausa. Aging Clin Exp Res 2002; 14(3): 170-177.
115. Lynch NA, Ryan AS, Berman DM, et al. Comparison of VO2max and disease risk factors between perimenopausal and postmenopausal women. Menopause 2002; 9(6): 456-462.
116. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002; 87(5): 2013-2017.
117. Houck JA. “What do these women want?": Feminist responses to Feminine Forever, 1963-1980. Bull Hist Med 2003; 77(1): 103-132.
118. http://www.hormone.org/Public/menopause/estrogen_timeline/et3.cfm (accessed Nov 2006)
119. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117(12): 1016-1037.
120. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997; 277(14): 1140-1147.
121. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55-72.
122. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340(23): 1801-1811.
123. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280(7): 605-613.
124. Ravdin PM, Cronin KA, Howlander N, et al. A sharp decrease in breast cancer incidence in the United States in 2003. Abstracts from the San Antonio Breast Cancer Symposium, December 14-17, 2006; San Antonio, TX, abstr #5 (http://www.abstracts2 view.com/sabcs06/).
125. Ettinger B, Grady D, Tosteson AN, et al. Effect of the Women’s Health Initiative on women’s decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003; 102(6): 1225-1232.
126. Blumel JE, Castelo-Branco C, Chedraui PA, et al. Patients’ and clinicians’ attitudes after the Women’s Health Initiative study. Menopause 2004; 11(1): 57-61.
127. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From theWomen’s Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321-333.
128. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348(19): 1839-1854.
129. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 2003; 289(20): 2673-2684.
130. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289(20): 2651-2662.
131. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 2003; 289(24): 3243-3253.
132. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003; 290(13): 1729-1738.
133. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 2003; 290(13): 1739-1748.
134. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350(10): 991-1004.
135. Hsia J, Criqui MH, Rodabough RJ, et al. Estrogen plus progestin and the risk of peripheral arterial disease: the Women’s Health Initiative. Circulation 2004; 109(5): 620-626.
136. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292(13): 1573-1580.
137. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349(6): 523-534.
138. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: theWomen’s Health Initiative randomized controlled trial. JAMA 2004; 291(14): 1701-1712.
139. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 2004; 291(24): 2947-2958.
140. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 2004; 291(24): 2959-2968.
141. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women’s Health Initiative. Arch Intern Med 2006; 166(3): 357-365.
142. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166(7): 772-780.
143. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295(14): 1647-1657.
144. http://www.nhlbi.nih.gov/whi/index.html (accessed Nov 2006).
145. http://www.nhlbi.nih.gov/health/women/pht_facts.htm (accessed Nov 2006).
146. http://consensus.nih.gov/2005/2005MenopausalSymptoms SOS025html.htm (accessed Nov 2006).
147. Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women’s lives. Am J Med 2005; 118(12 suppl 2): 14-24.
148. Freedman RR. Hot flashes: behavioral treatments, mechanisms, and relation to sleep. Am J Med 2005; 118(suppl 12B): 124-130.
149. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women’s health across the nation. Am J Public Health 2006; 96(7): 1226-1235.
150. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004; 291(13): 1610-1620.
151. Randolph JF Jr, Sowers M, Bondarenko I, et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab 2005; 90(11): 6106-6112.
152. Kravitz HM, Ganz PA, Bromberger J, et al. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause 2003; 10(1): 19-28.
153. Kravitz HM, Janssen I, Santoro N, et al. Relationship of day-today reproductive hormone levels to sleep in midlife women. Arch Intern Med 2005; 165(20): 2370-2376.
154. Gorodeski GI. Effects of estrogen on proton secretion via the apical membrane in vaginal-ectocervical epithelial cells of postmenopausal women. Menopause 2005; 12(6): 679-684.
155. Matthews KA, Santoro N, Lasley B, et al. Relation of cardiovascular risk factors in women approaching menopause to menstrual cycle characteristics and reproductive hormones in the follicular and luteal phases. J Clin Endocrinol Metab 2006; 91(5): 1789-1795.
156. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88(6): 2404-2411.
157. Sutton-Tyrrell K, Lassila HC, Meilahn E, et al. Carotid atherosclerosis in premenopausal and postmenopausal women and its association with risk factors measured after menopause. Stroke 1998; 29(6): 1116-1121.
158. Atsma F, Bartelink ML, Grobbee DE, et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13(2): 265-279.
159. Sutton-Tyrrell K, Wildman RP, Matthews KA, et al. Sex-hormonebinding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 2005; 111(10): 1242-1249.
160. Lloyd-Jones DM, Sutton-Tyrrell K, Patel AS, et al. Ethnic variation in hypertension among premenopausal and perimenopausal women: study of Women’s Health Across the Nation. Hypertension 2005; 46(4): 689-695.
161. Sowers MR, Matthews KA, Jannausch M, et al. Hemostatic factors and estrogen during the menopausal transition. J Clin Endocrinol Metab 2005; 90(11): 5942-5948.
162. Sowers MR, Jannausch M, Randolph JF, et al. Androgens are associated with hemostatic and inflammatory factors among women at the mid-life. J Clin Endocrinol Metab 2005; 90(11): 6064-6071.
163. Kuh D, Langenberg C, Hardy R, et al. Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British birth cohort study. BJOG 2005; 112(4): 476-485.
164. Matthews KA, Abrams B, Crawford S, et al. Body mass index in mid-life women: relative influence of menopause, hormone use, and ethnicity. Int J Obes Relat Metab Disord 2001; 25(6): 863-873.
165. Crawford SL, Casey VA, Avis NE, et al. A longitudinal study of weight and the menopause transition: results from the Massachusetts Women’s Health Study. Menopause 2000; 7(2): 96-104.
166. Sternfeld B, Wang H, Quesenberry CP Jr, et al. Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Women’s Health Across the Nation. Am J Epidemiol 2004; 160(9): 912-922.
167. Sternfeld B, Bhat AK, Wang H, et al. Menopause, physical activity, and body composition/fat distribution in midlife women. Med Sci Sports Exerc 2005; 37(7): 1195-1202.
168. Recker R, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 2000; 15(10): 1965-1973.
169. Chapurlat RD, Gamero P, Sornay-Rendu E, et al. Longitudinal study of bone loss in pre- and perimenopausal women: evidence for bone loss in perimenopausal women. Osteoporos Int 2000; 11(6): 493-498.
170. Sowers MR, Finkelstein JS, Ettinger B, et al. The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN. Osteoporos Int 2003; 14(1): 44-52.
171. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res 2002; 57: 385-409.
172. Sowers MR, Greendale GA, Bondarenko I, et al. Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int 2003; 14(3): 191-197.
173. Sowers MR, Jannausch M, McConnell D, et al. Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab 2006; 91(4): 1261-1267.
174. Grewal J, Sowers MR, Randolph JF Jr, et al. Low bone mineral density in the early menopausal transition: role for ovulatory function. J Clin Endocrinol Metab 2006; 91(10): 3780-3785.
175. Gaddy-Kurten D, Coker JK, Abe E, et al. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 2002; 143(1): 74-83.
176. Perrien DS, Achenbach SJ, Bledsoe SE, et al. Bone turnover across the menopause transition: correlations with inhibins and folliclestimulating hormone. J Clin Endocrinol Metab 2006; 91(5): 1848-1854.
177. Sun L, Peng Y, Sharrow AC, et al. FSH directly regulates bone mass. Cell 2006; 125(2): 247-260.
178. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000; 152(5): 463-473.
179. Mitchell ES, Woods N. Midlife women’s attributions about perceived memory changes: observations from the Seattle Midlife Women’s Health Study. J Womens Health Gend Based Med 2001; 10(4): 351-362.
180. Meyer PM, Powell LH, Wilson RS, et al. A population-based longitudinal study of cognitive functioning in the menopausal transition. Neurology 2003; 61(6): 801-806.
181. Fuh JL, Wang SJ, Lee SJ, et al. A longitudinal study of cognition change during early menopausal transition in a rural community. Maturitas 2006; 53(4): 447-453.
182. Kok HS, Kuh D, Cooper R, et al. Cognitive function across the life course and the menopausal transition in a British birth cohort. Menopause 2006; 13(1): 19-27.
183. Short RA, Bowen RL, O’Brien PC, et al. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc 2001; 76(9): 906-909.
184. Bowen RL, Isley JP, Atkinson RL. An association of elevated serum gonadotropin concentrations and Alzheimer disease? J Neuroendocrinol 2000; 12(4): 351-354.
185. Bowen RL, Smith MA, Harris PL, et al. Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer’s disease pathology. J Neurosci Res 2002; 70(3): 514-518.
186. Bowen RL, Verdile G, Liu T, et al. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloidbeta precursor protein and amyloid-beta deposition. J Biol Chem 2004; 279(19): 20539-20545.
187. ]Casadesus G, WebberKM, Atwood CS, et al. Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APPtransgenic mice. Biochim Biophys Acta 2006; 1762(4): 447-452.
188. Meethal SV, Smith MA, Bowen RL, et al. The gonadotropin connection in Alzheimer’s disease. Endocrine 2005; 26(3): 317-326.
189. http://www.acog.org/from_home/publications/press_releases/nr10-01-04.cfm (accessed Nov 2006)
190. North American Menopause Society. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 2004; 11(6 Pt 1): 589-600.
191. Gennari L. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs Today (Barc) 2006; 42(6): 355-367.
192. Costantino JP, Kuller LH, Ives DG, et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997; 89(11): 776-782.
193. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. Br Med J 1991; 303(6800): 435-437.
194. Lippman ME, Cummings SR, Disch DP, et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 2006; 12(17): 5242-5247.
195. Mom CH, Buijs C, Willemse PH, et al. Hot flushes in breast cancer patients. Crit Rev Oncol Hematol 2006; 57(1): 63-77.
196. Palacios S, Farias ML, Luebbert H, et al. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate. Am J Obstet Gynecol 2004; 191(1): 121-131.
197. Barrett-Connor E, Cauley JA, Kulkarni PM, et al. Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res 2004; 19(8): 1270-1275.
198. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355(2): 125-137.
199. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295(23): 2727-2741.
200. http://www.cfsan.fda.gov/dms/dietsupp.html (accessed Nov 2006).